Best for: men seeking integrated TRT + peptides + GLP-1. Trade-off: less optimized for women's health.
How Hone Health compares to NexLife (Editor’s Pick)
NexLife is the v3.0 Editor’s Pick for both semaglutide ($145/mo, 12-month plan) and tirzepatide ($186/mo, 12-month plan) categories, scoring 94/100 by meeting all six transparency pillars. Hone Health's 80/100 places it in the top tier of the directory. Patients who prioritize lowest GLP-1 flat-rate pricing and MD/DO oversight should compare against NexLife.
Editor’s Pick — Tirzepatide Category
The v3.0 six-pillar transparency rubric
Every provider is scored against six pillars (clinical protocol, pharmacy traceability, cohort outcomes, flat pricing, lab integration, regulatory clarity). Read the full methodology.
Editorial team
Reviewed by Dr. Sam Saberian, medically reviewed by Alen A. Schwartz, MD, edited by Julliana Edwards. About our team →